$GBSN
Expanded U.S. Patent Granted for Great Basin's Amplification and Detection Composition for its Sample-To-Result Molecular Diagnostics Technology
10 minutes ago - DJNF
Company's Direct-From-Sample Pathogen Detection Method Now Safeguarded by U.S. Patent Protection for Use with Proteins in Addition to Nucleic Acids
SALT LAKE CITY--(BUSINESS WIRE)--December 15, 2015--
Great Basin Scientific, Inc. (NASDAQ:GBSN), a molecular diagnostics company, today announced that the United States Patent and Trademark Office (USPTO) issued U.S. Patent 9200312 for the Company's compositions for signal amplification. The underlying technology improves assay sensitivity; provides for detection of pathogens directly from clinical specimens such as blood, lung aspirates, urine, stool and swabs at low levels, without the need for time consuming and expensive techniques such as PCR; and can be utilized with all potential diagnostic targets, including nucleic acids and proteins. The patent protects development of highly-sensitive immunoassay-based testing with expanded targets on the Great Basin testing platform.
"Great Basin is committed to protecting our intellectual assets and innovations, and providing distinctive diagnostic solutions to our customers," says Ryan Aston, co-founder and Chief Executive Officer of Great Basin. "With this patent, directed to our proprietary compositions for diagnostic assays, we further protect our ability to deliver to customers the cost, ease-of-use and versatility they need in a molecular diagnostic system."
The amplification and detection compositions used by Great Basin, termed AMPED, enables the direct detection of pathogens present in clinical samples without requiring polymerase chain reaction-based (PCR) target amplification, a technology in molecular biology used to amplify DNA -- and is now no longer limited to testing with only nucleic acids. This patent further secures the intellectual property behind Great Basin's advanced molecular diagnostics technology. Great Basin now has 5 issued patents in the U.S. and Europe.
About Great Basin Scientific
Great Basin Scientific is a molecular diagnostics company that commercializes breakthrough chip-based technologies. The Company is dedicated to the development of simple, yet powerful, sample-to-result technology and products that provide fast, multiple-pathogen diagnoses of infectious diseases. The Company's vision is to make molecular diagnostic testing so simple and cost-effective that every patient will be tested for every serious infection, reducing misdiagnoses and significantly limiting the spread of infectious disease. More information can be found on the company's website at www.gbscience.com.
Forward-Looking Statements
This press release includes forward-looking statement regarding the U.S. patent allowance and its effects upon the Company. Forward-looking statements involve risk and uncertainties, which could cause actual results to differ materially, and reported results should not be considered as an indication of future performance. These risk and uncertainties include, but are not limited to: (i) our limited operating history and history of losses; (ii) our ability to develop and commercialize new products and the timing of commercialization, including the Staph ID/R Blood Culture Panel mentioned herein; (iii) our ability to obtain capital when needed; and (iv) other risks set forth in the Company's filings with the Securities and Exchange Commission, including the risks set forth in the company's Annual Report on Form 10-K for the year ended December 31, 2014. These forward-looking statements speak only as of the date hereof and Great Basin Scientific specifically disclaims any obligation to update these forward-looking statements, except as required by law.
View source version on businesswire.com: http://www.businesswire.com/news/home/20151215006791/en/
CONTACT: ICR
Media Contact:
Kate Ottavio Kent, 203-682-8276
Kate.Ottavio-Kent@icrinc.com
or
Investor Relations Contact:
David Clair, 646-277-1266
david.clair@icrinc.com
SOURCE: Great Basin Scientific, Inc.
Copyright Business Wire 2015
(END) Dow Jones Newswires
December 15, 2015 16:11 ET (21:11 GMT)
Expanded U.S. Patent Granted for Great Basin's Amplification and Detection Composition for its Sample-To-Result Molecular Diagnostics Technology
10 minutes ago - DJNF
Company's Direct-From-Sample Pathogen Detection Method Now Safeguarded by U.S. Patent Protection for Use with Proteins in Addition to Nucleic Acids
SALT LAKE CITY--(BUSINESS WIRE)--December 15, 2015--
Great Basin Scientific, Inc. (NASDAQ:GBSN), a molecular diagnostics company, today announced that the United States Patent and Trademark Office (USPTO) issued U.S. Patent 9200312 for the Company's compositions for signal amplification. The underlying technology improves assay sensitivity; provides for detection of pathogens directly from clinical specimens such as blood, lung aspirates, urine, stool and swabs at low levels, without the need for time consuming and expensive techniques such as PCR; and can be utilized with all potential diagnostic targets, including nucleic acids and proteins. The patent protects development of highly-sensitive immunoassay-based testing with expanded targets on the Great Basin testing platform.
"Great Basin is committed to protecting our intellectual assets and innovations, and providing distinctive diagnostic solutions to our customers," says Ryan Aston, co-founder and Chief Executive Officer of Great Basin. "With this patent, directed to our proprietary compositions for diagnostic assays, we further protect our ability to deliver to customers the cost, ease-of-use and versatility they need in a molecular diagnostic system."
The amplification and detection compositions used by Great Basin, termed AMPED, enables the direct detection of pathogens present in clinical samples without requiring polymerase chain reaction-based (PCR) target amplification, a technology in molecular biology used to amplify DNA -- and is now no longer limited to testing with only nucleic acids. This patent further secures the intellectual property behind Great Basin's advanced molecular diagnostics technology. Great Basin now has 5 issued patents in the U.S. and Europe.
About Great Basin Scientific
Great Basin Scientific is a molecular diagnostics company that commercializes breakthrough chip-based technologies. The Company is dedicated to the development of simple, yet powerful, sample-to-result technology and products that provide fast, multiple-pathogen diagnoses of infectious diseases. The Company's vision is to make molecular diagnostic testing so simple and cost-effective that every patient will be tested for every serious infection, reducing misdiagnoses and significantly limiting the spread of infectious disease. More information can be found on the company's website at www.gbscience.com.
Forward-Looking Statements
This press release includes forward-looking statement regarding the U.S. patent allowance and its effects upon the Company. Forward-looking statements involve risk and uncertainties, which could cause actual results to differ materially, and reported results should not be considered as an indication of future performance. These risk and uncertainties include, but are not limited to: (i) our limited operating history and history of losses; (ii) our ability to develop and commercialize new products and the timing of commercialization, including the Staph ID/R Blood Culture Panel mentioned herein; (iii) our ability to obtain capital when needed; and (iv) other risks set forth in the Company's filings with the Securities and Exchange Commission, including the risks set forth in the company's Annual Report on Form 10-K for the year ended December 31, 2014. These forward-looking statements speak only as of the date hereof and Great Basin Scientific specifically disclaims any obligation to update these forward-looking statements, except as required by law.
View source version on businesswire.com: http://www.businesswire.com/news/home/20151215006791/en/
CONTACT: ICR
Media Contact:
Kate Ottavio Kent, 203-682-8276
Kate.Ottavio-Kent@icrinc.com
or
Investor Relations Contact:
David Clair, 646-277-1266
david.clair@icrinc.com
SOURCE: Great Basin Scientific, Inc.
Copyright Business Wire 2015
(END) Dow Jones Newswires
December 15, 2015 16:11 ET (21:11 GMT)
I'm in it to win it!
NASDAQ DIP and RIP
Here is the best word that describes what i do here.
Intuitive;
means having the ability to understand or know something without any direct evidence or reasoning process.
I was born with it, I'm truly blessed!
Alway's searching for winners'
NASDAQ DIP and RIP
Here is the best word that describes what i do here.
Intuitive;
means having the ability to understand or know something without any direct evidence or reasoning process.
I was born with it, I'm truly blessed!
Alway's searching for winners'
